Gynecologic oncology

publication venue for

Diagnosis and management of an endometrial cancer patient with Cowden syndrome. 2021
Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. 2019
Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor. 2018
Corrigendum to "Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center" [Gynecol. Oncol. 142 (2016) 13-18]. 2016
A case of monophasic synovial sarcoma presenting as a vulvar mass. 2005
Full-thickness diaphragmatic resection for stage IV ovarian carcinoma using the EndoGIA stapling device followed by diaphragmatic reconstruction using a Gore-tex graft: a case report and review of the literature. 2005
Conservative management of pneumatosis intestinalis. 2005
Celiac disease presenting as a paraneoplastic syndrome in a patient with synchronous endometrial and ovarian cancers. 2005
Borderline endometrioid tumor arising in a paratubal cyst: a case report. 2005
Bilateral peripheral T-cell lymphoma of the fallopian tubes. 2004
Chemotherapy-induced dyspareunia: a case study of vaginal mucositis and pegylated liposomal doxorubicin injection in advanced stage ovarian carcinoma. 2004
Radical trachelectomy via a trans-sacral approach: a case report. 2003
Epithelioid sarcoma of the uterine cervix. 2003
The use of MRI in the diagnosis and management of a bulky cervical carcinoma. 2003
Vaginal evisceration after hysterectomy: the repair by a laparoscopic and vaginal approach with a omental flap. 2003
Clinically inapparent invasive vulvar carcinoma in an area of persistent Paget's disease: a case report. 2003
Major hepatectomy at interval debulking for stage IV ovarian carcinoma: a case report. 2002
Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin. 2000
Prolonged remission of recurrent, metastatic placental site trophoblastic tumor after chemotherapy. 2000
Ovarian carcinoma initially presenting as metastatic axillary lymphadenopathy. 1997
Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue. 1997
Late recurrences of vaginal clear cell adenocarcinoma. 1996
Effect of combination chemotherapy with cisplatin and cyclophosphamide on human immunodeficiency virus type-1 surrogate markers in a patient with advanced epithelial ovarian cancer. 1995
Perforation of the inferior vena cava by a recently inserted Greenfield filter. 1995
ACT-ON: Assisted cascade testing via outreach and navigation - Real-world experience with clinician-facilitated cascade testing.. 207S. 2026
Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263).. 202. 2025
Virtual versus reality: Assessing the accuracy of a digital cancer risk assessment tool in a gynecologic oncology clinic.. 200. 2025
Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?. 201. 2025
Timely targeted testing for hereditary cancer syndromes - Importance of clinician-facilitated cascade testing in the first year post-diagnosis.. 190. 2024
Beyond the decision: Reproductive justice and cervical cancer care in a post-Dobbs era.. 190. 2024
Personalized survivorship care: Routine breast cancer risk assessment in the gynecologic oncology clinic.. 183. 2024
Reduced healthcare access contributes to delay of care in endometrial cancer.. 182. 2024
Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement.. 181. 2024
Building knowledge using a novel web-based intervention to promote HPV vaccination in a diverse, low-income population.. 181. 2024
Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials.. 181. 2023
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.. 180. 2023
Germline drivers of gynecologic carcinosarcomas.. 174. 2023
Web-based tool for cancer family history collection: A prospective randomized controlled trial.. 173. 2023
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.. 170. 2023
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.. 166. 2022
Relative importance of individual insurance status and hospital payer mix on survival for women with cervical cancer.. 166. 2022
COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic.. 164. 2021
Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.. 163. 2021
Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.. 162. 2021
Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.. 161. 2021
Underrepresented minority representation trends in gynecologic oncology fellowships in the United States.. 160. 2020
Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic.. 160. 2020
Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals.. 159. 2020
Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection.. 159. 2020
Sexual harassment and gender discrimination in gynecologic oncology.. 159. 2020
Electronic patient-reported symptom monitoring in patients recovering from ambulatory minimally invasive gynecologic surgery: A prospective pilot study.. 159. 2020
A single-arm clinical trial investigating the effectiveness of a non-hormonal, hyaluronic acid-based vaginal moisturizer in endometrial cancer survivors.. 158. 2020
Promoting health equity in the era of COVID-19.. 158. 2020
Impact of hospital volume on surgical management and outcomes for early-stage cervical cancer.. 157. 2020
Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression.. 157. 2020
Primary malignant ovarian carcinoid; management and outcomes.. 157. 2020
Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy.. 156. 2019
Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.. 156. 2019
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.. 156. 2019
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.. 156. 2019
Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer.. 155. 2019
Secondary surgical resection for patients with recurrent uterine leiomyosarcoma.. 154. 2019
Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.. 154. 2019
Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.. 154. 2019
Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center.. 154. 2019
Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis.. 153. 2019
Hospice utilization in advanced cervical malignancies: An analysis of the National Inpatient Sample.. 152. 2018
Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.. 152. 2018
A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer.. 151. 2018
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.. 151. 2018
A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study.. 151. 2018
Missed opportunities: Genetic counseling and testing among an ethnically diverse cohort of women with endometrial cancer.. 151. 2018
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.. 150. 2018
Laparoscopy decreases the disparity in postoperative complications between black and white women after hysterectomy for endometrial cancer.. 149. 2018
An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative.. 148. 2018
Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers.. 148. 2018
Fertility-preserving surgery for advanced stage ovarian germ cell tumors.. 147. 2017
Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.. 147. 2017
Genetic predisposition to bevacizumab-induced hypertension.. 147. 2017
Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.. 147. 2017
Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base.. 147. 2017
Endometrial cancer surveillance adherence reduces utilization and subsequent costs.. 146. 2017
Should epithelial ovarian carcinoma metastatic to the inguinal lymph nodes be assigned stage IVB?. 147. 2017
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.. 146. 2017
Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum.. 146. 2017
Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach.. 146. 2017
Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.. 146. 2017
YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy.. 145. 2017
Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care.. 145. 2017
Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.. 145. 2017
Prevalence of lymph node metastasis and prognostic significance of lymphadenectomy in apparent early-stage malignant ovarian sex cord-stromal tumors.. 145. 2017
Primary lymphoma of the female genital tract: An analysis of 697 cases.. 145. 2017
Potential immunotherapy targets in recurrent cervical cancer.. 145. 2017
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.. 144. 2017
Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.. 144. 2016
Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma.. 144. 2016
A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.. 144. 2016
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.. 144. 2016
Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer: Analysis of the National Cancer Data Base.. 144. 2016
Survival of women with Mullerian adenosarcoma: A National Cancer Data Base study.. 143. 2016
The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status.. 143. 2016
Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.. 143. 2016
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.. 143. 2016
Room for improvement: An examination of advance care planning documentation among gynecologic oncology patients.. 142. 2016
The safety of same-day discharge after laparoscopic hysterectomy for endometrial cancer.. 142. 2016
Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.. 142. 2016
Malignant Brenner tumors of the ovary; a population-based analysis.. 142. 2016
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.. 141. 2016
Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery.. 141. 2016
Adjuvant radiation therapy in uterine carcinosarcoma: A population-based analysis of patient demographic and clinical characteristics, patterns of care and outcomes.. 141. 2016
Natural history and outcome of neuroendocrine carcinoma of the cervix.. 141. 2016
Epidemiology and outcomes of squamous ovarian carcinoma; a population-based study.. 141. 2016
The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer.. 140. 2016
Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.. 140. 2016
Magnitude of risk for nodal metastasis associated with lymphvascular space invasion for endometrial cancer.. 140. 2016
Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.. 139. 2015
Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening.. 139. 2015
Development of a risk stratification system to guide treatment for female germ cell tumors.. 138. 2015
Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.. 138. 2015
Patient and physician factors associated with participation in cervical and uterine cancer trials: an NRG/GOG247 study.. 138. 2015
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.. 138. 2015
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.. 137. 2015
Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD).. 137. 2015
The role of systemic chemotherapy in the management of granulosa cell tumors.. 136. 2014
Distribution and case-fatality ratios by cell-type for ovarian carcinomas: a 22-year series of 562 patients with uniform current histological classification.. 136. 2014
Lymphatic mapping and sentinel lymph node dissection compared to complete lymphadenectomy in the management of early-stage vulvar cancer: A cost-utility analysis.. 136. 2014
Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.. 136. 2014
Teaching gynecologic oncology in Low resource settings: a collaboration of health volunteers overseas and the society of gynecologic oncology.. 135. 2014
A qualitative study of ovarian cancer survivors' perceptions of endpoints and goals of care.. 135. 2014
AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer.. 135. 2014
Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma.. 135. 2014
A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.. 134. 2014
A comparison of colorimetric versus fluorometric sentinel lymph node mapping during robotic surgery for endometrial cancer.. 134. 2014
Feasibility and perioperative outcomes of robotic-assisted surgery in the management of recurrent ovarian cancer: a multi-institutional study.. 134. 2014
The feasibility and safety of same-day discharge after robotic-assisted hysterectomy alone or with other procedures for benign and malignant indications.. 133. 2014
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.. 133. 2014
Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.. 133. 2014
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.. 132. 2014
Fellowship learning curve associated with completing a robotic assisted total laparoscopic hysterectomy.. 132. 2013
Lymphatic and nerve distribution throughout the parametrium.. 131. 2013
Reporting of quality measures in gynecologic oncology programs at Prospective Payment System (PPS)-Exempt Cancer Hospitals: an early glimpse into a challenging initiative.. 130. 2013
The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration.. 129. 2013
Management of uterine adenosarcomas with and without sarcomatous overgrowth.. 129. 2012
Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome.. 129. 2012
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.. 129. 2012
Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173.. 128. 2012
Validated gene targets associated with curatively treated advanced serous ovarian carcinoma.. 128. 2012
Endocervical involvement in endometrial adenocarcinoma is not prognostically significant and the pathologic assessment of the pattern of involvement is not reproducible.. 128. 2012
A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.. 127. 2012
Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix.. 127. 2012
Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma.. 128. 2012
High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes.. 127. 2012
Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.. 126. 2012
Anterior pelvic exenteration with total vaginectomy for recurrent or persistent genitourinary malignancies: review of surgical technique, complications, and outcome.. 126. 2012
Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.. 125. 2012
Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.. 125. 2012
Extended pelvic resections for recurrent or persistent uterine and cervical malignancies: an update on out of the box surgery.. 125. 2012
Lymphatic ascites following pelvic and paraaortic lymphadenectomy procedures for gynecologic malignancies.. 125. 2011
Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma.. 124. 2011
Quality of life in cervical cancer survivors: patient and provider perspectives on common complications of cervical cancer and treatment.. 125. 2011
CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study.. 124. 2011
A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.. 124. 2011
The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma.. 123. 2011
The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study.. 123. 2011
Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.. 122. 2011
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.. 123. 2011
The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC).. 123. 2011
Surgical cytoreduction in stage IV endometrioid endometrial carcinoma.. 122. 2011
Malignant melanoma of the vulva: an extension of cutaneous melanoma?. 122. 2011
Incidence of lymph node and adnexal metastasis in endometrial stromal sarcoma.. 121. 2011
Clinical predictors of bevacizumab-associated gastrointestinal perforation.. 120. 2010
"Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer.. 120. 2010
MMP-1-PAR1 axis mediates LPA-induced epithelial ovarian cancer (EOC) invasion.. 120. 2010
Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors.. 120. 2010
Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers.. 120. 2010
Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment.. 120. 2010
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.. 119. 2010
Upstaging pathologic stage I ovarian carcinoma based on dense adhesions is not warranted: a clinicopathologic study of 84 patients originally classified as FIGO stage II.. 119. 2010
Cognitive functions in long-term survivors of ovarian cancer.. 119. 2010
The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm.. 118. 2010
Use of multimedia as an educational tool to improve human papillomavirus vaccine acceptability--a pilot study.. 118. 2010
Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series.. 117. 2010
A pilot study using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a clinical care tool to identify lower extremity lymphedema in gynecologic cancer survivors.. 117. 2010
Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?. 117. 2010
Single photon emission computed tomography SPECT-CT improves sentinel node detection and localization in cervical and uterine malignancy.. 117. 2010
The accuracy of magnetic resonance imaging in staging of vulvar cancer: a retrospective multi-centre study.. 117. 2010
Lysophosphatidic acid (LPA) effects on endometrial carcinoma in vitro proliferation, invasion, and matrix metalloproteinase activity.. 117. 2010
Consolidation strategies in ovarian cancer: observations for future clinical trials.. 116. 2010
The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.. 116. 2009
Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.. 116. 2009
Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.. 116. 2009
Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.. 116. 2009
Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.. 115. 2009
Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.. 115. 2009
VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion.. 115. 2009
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.. 115. 2009
Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer.. 115. 2009
Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma.. 114. 2009
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.. 113. 2009
Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass.. 112. 2008
Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian, peritoneal and fallopian tube cancer.. 112. 2008
Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer.. 111. 2008
Early invasive cervical cancer: MRI and CT predictors of lymphatic metastases in the ACRIN 6651/GOG 183 intergroup study.. 112. 2008
LPA receptor 2 mediates LPA-induced endometrial cancer invasion.. 112. 2008
A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.. 111. 2008
Upper abdominal surgical procedures: liver mobilization and diaphragm peritonectomy/resection, splenectomy, and distal pancreatectomy.. 111. 2008
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.. 110. 2008
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.. 109. 2008
S1P induced changes in epithelial ovarian cancer proteolysis, invasion, and attachment are mediated by Gi and Rac.. 110. 2008
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.. 109. 2008
Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era.. 109. 2008
Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner.. 108. 2008
Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.. 108. 2008
Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series.. 108. 2008
Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer.. 108. 2007
Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis.. 107. 2007
S1P and LPA have an attachment-dependent regulatory effect on invasion of epithelial ovarian cancer cells.. 107. 2007
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.. 106. 2007
The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.. 106. 2007
The Bethesda System 2001 recommendation for reporting of benign appearing endometrial cells in Pap tests of women age 40 years and older leads to unwarranted surveillance when followed without clinical qualifiers.. 107. 2007
A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model.. 107. 2007
Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer.. 106. 2007
Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.. 106. 2007
A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration.. 106. 2007
The role of cytoreductive surgery for colon cancer metastatic to the ovary.. 105. 2007
Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.. 105. 2007
Extended pelvic resection of iliacus muscle and femoral nerve for isolated recurrent uterine cancer.. 104. 2006
Superior pubic rami resection for isolated recurrent uterine cancer.. 104. 2006
Distal partial gastrectomy and gastrojejunal anastomosis for recurrent ovarian cancer.. 104. 2006
Hand-assisted laparoscopic splenectomy for isolated ovarian cancer recurrence.. 104. 2006
Liver mobilization and diaphragm peritonectomy/resection.. 104. 2006
Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.. 104. 2006
Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier: a cost-effectiveness analysis.. 104. 2006
The outcomes of patients with positive margins after excision for intraepithelial Paget's disease of the vulva.. 104. 2006
Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.. 104. 2006
Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome.. 104. 2006
S1P regulation of ovarian carcinoma invasiveness.. 103. 2006
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.. 103. 2006
Uterine cancer in Maryland: impact of surgeon case volume and other prognostic factors on short-term mortality.. 103. 2006
Clinicopathologic features of early adenocarcinoma of the cervix initially managed with cervical conization.. 103. 2006
Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.. 103. 2006
Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer.. 103. 2006
Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance.. 103. 2006
Salvage cytoreductive surgery for recurrent endometrial cancer.. 103. 2006
Surgical resection of recurrent endometrial carcinoma.. 102. 2006
Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning.. 102. 2006
The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy.. 102. 2006
Cancer-related infertility.. 99. 2005
Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma.. 101. 2005
Placental site trophoblastic tumor: A study of 55 cases and review of the literature emphasizing factors of prognostic significance.. 100. 2005
Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study.. 99. 2005
Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.. 100. 2005
Surgical care of elderly women with ovarian cancer: a population-based perspective.. 99. 2005
LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2).. 97. 2005
Laparoscopic lymphadenectomy for gynecologic malignancies using ultrasonically activated shears: analysis of first 100 cases.. 97. 2005
Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study.. 96. 2005
Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma.. 96. 2005
Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer.. 96. 2005
Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis.. 96. 2005
Evaluation of germline PTEN mutations in endometrial cancer patients.. 96. 2005
Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group.. 95. 2004
Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.. 95. 2004
The use of colorectal stents for palliation of large-bowel obstruction due to recurrent gynecologic cancer.. 95. 2004
Upregulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes.. 95. 2004
Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8.. 95. 2004
Reoperation for palliation of recurrent malignant bowel obstruction in ovarian carcinoma.. 95. 2004
Tertiary cytoreduction in patients with recurrent ovarian carcinoma.. 95. 2004
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.. 94. 2004
Laparoscopic restaging of early stage invasive adnexal tumors: a 10-year experience.. 94. 2004
Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray.. 94. 2004
Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.. 93. 2004
A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians.. 93. 2004
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.. 93. 2004
A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.. 93. 2004
Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer.. 93. 2004
Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.. 93. 2004
Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy.. 91. 2003
Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.. 91. 2003
Resection of recurrent ovarian or fallopian tube carcinoma involving the liver.. 91. 2003
Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus.. 91. 2003
Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy.. 91. 2003
A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer.. 90. 2003
Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life.. 89. 2003
Palliative surgery for bowel obstruction in recurrent ovarian cancer:an updated series.. 89. 2003
Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy.. 89. 2003
Laparoscopic identification of sentinel lymph nodes in early stage cervical cancer: prospective study using a combination of patent blue dye injection and technetium radiocolloid injection.. 89. 2003
Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma.. 87. 2002
Craniotomy for central nervous system metastases in epithelial ovarian carcinoma.. 87. 2002
Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer.. 85. 2002
Preoperative CA-125 levels in patients with hereditary compared to sporadic epithelial ovarian carcinoma.. 84. 2002
Identification of prognostic factors in advanced epithelial ovarian carcinoma.. 82. 2001
The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients.. 82. 2001
Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction.. 82. 2001
Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.. 81. 2001
Complications associated with intraperitoneal chemotherapy catheters.. 81. 2001
Epithelial ovarian carcinoma and European birthplace of grandparents.. 81. 2001
High incidence of positive peritoneal cytology in low-risk endometrial cancer treated by laparoscopically assisted vaginal hysterectomy.. 80. 2001
Risk of endometrial carcinoma associated with BRCA mutation.. 80. 2001
Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.. 80. 2001
Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Müllerian serous carcinomas: clinical divergence without immunophenotypic differences.. 79. 2000
Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.. 79. 2000
Continent urinary diversion and low-rectal anastomosis in patients undergoing exenterative procedures for recurrent gynecologic malignancies.. 78. 2000
The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.. 77. 2000
Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.. 73. 1999
The accuracy of frozen-section diagnosis in metastatic breast and colorectal carcinoma to the adnexa.. 73. 1999
Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists.. 71. 1998
Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study.. 70. 1998
A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment.. 69. 1998
Enhanced radiosensitization with interferon-alpha-2b and cisplatin in the treatment of locally advanced cervical carcinoma.. 67. 1997
Biochemical characterization of primary peritoneal carcinoma cell adhesion, migration, and proteinase activity.. 67. 1997
Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer.. 67. 1997
High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.. 67. 1997
The role of surgical cytoreduction in Stage IV endometrial carcinoma.. 67. 1997
Infrared spectroscopy of normal and abnormal cervical smears: evaluation by principal component analysis.. 66. 1997
The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma.. 61. 1996
Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium.. 61. 1996
The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer.. 61. 1996
Extramammary Paget's disease of the vulva.. 56. 1995
Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer.. 51. 1993
Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.. 50. 1993
Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma.. 50. 1993
Impact of age on survival of patients with ovarian cancer.. 49. 1993
Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatment.. 49. 1993
The use of recombinant human erythropoietin to prevent carboplatin-induced anemia.. 49. 1993
Evidence for persistence of mitoxantrone within the peritoneal cavity following intraperitoneal delivery.. 48. 1993
High-resolution positron emission tomography of human ovarian cancer in nude rats using 124I-labeled monoclonal antibodies.. 48. 1993
Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer.. 47. 1992
Phase II trial of high-dose cisplatin with sodium thiosulfate nephroprotection in patients with advanced carcinoma of the uterine cervix previously untreated with chemotherapy.. 43. 1991
Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube.. 42. 1991
Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy.. 42. 1991
Late effects of cisplatin-based chemotherapy on renal function in patients with ovarian carcinoma.. 41. 1991
Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system.. 41. 1991
Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide.. 41. 1991
Chemotherapy-induced neutropenia and fever in patients receiving cisplatin-based chemotherapy for ovarian malignancy.. 40. 1991
Aggressive chemosurgical debulking in patients with advanced ovarian cancer.. 38. 1990
Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma.. 34. 1989
Advanced-stage endometrial cancer: contributions of estrogen use, smoking, and other risk factors.. 32. 1989
Nonoperative supravesical urinary diversion in obstetrics and gynecology.. 14. 1982
Nuclear magnetic resonance properties of gynecological tissues.. 6. 1978
Re: "Pelvic exenteration with curative intent for recurrent uterine malignancies".. 126. 2012
Re: "Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials".. 108. 2008
A primary ovarian leiomyosarcoma with micro-invasive features (stage I): is surgical excision enough?. 73. 1999
Re: defining the limits of radical cytoreductive surgery in ovarian cancer. 2012
RE: "Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers". 2011
In response to: Establishing evidence for change in ovarian cancer surgery - Proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis. 2009
Observation on the surgical aspect of resection of noncolorectal nonneuroendocrine hepatic parenchymal metastasis in patients with primary epithelial ovarian carcinoma. 2009
Does a diagnosis of breast cancer reduce ovarian cancer risk in BRCA1/2 3 carriers: Why is this a question?. 201. 2025
MUTYH: Possibly another important gene in ovarian cancer?. 196. 2025
Clinical trials are not the solution to inequities in cancer care.. 192. 2025
Achieving diversity in clinical trial enrollment by reducing burden and increasing value: A patient-centered approach.. 172. 2023
State of the science: Uterine sarcomas: From pathology to practice.. 159. 2020
Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward…or too much risk?. 157. 2020
Coronavirus concerns: What do women with gynecologic cancer need to know during the COVID-19 crisis?. 158. 2020
Difficult Choices in Stage I Uterine Leiomyosarcoma- it's okay to "stand there".. 147. 2017
Venous thromboembolism and minimally invasive surgery in gynecologic oncology: time to re-evaluate and refocus.. 134. 2014
Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Developed by the Society of Gynecologic Oncology's Clinical Practice Robotics Task Force.. 124. 2011
Advances in the management of endometrial carcinoma.. 120. 2011
Investigating women with suspected ovarian cancer.. 108. 2007
The role of bevacizumab in ovarian cancer--an evolving story.. 102. 2006
Is observation and salvage (when necessary) an appropriate approach to intermediate risk endometrial cancer?. 89. 2003
Is transvaginal ultrasound effective for screening asymptomatic women for the detection of early-stage epithelial ovarian carcinoma?. 77. 2000
Clarity and confusion regarding adjuvant radiation therapy in early endometrial cancer.. 75. 1999
Indications for and complications of transfusion and the management of gynecologic malignancies. 2017
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. 2015
Role of pegylated liposomal doxorubicin in ovarian cancer. 2005
Risk of melanoma among people with BRCA1 and BRCA2 pathogenic variants: A systematic review and meta-analysis. 2025
Creating work environments where people of all genders in gynecologic oncology can thrive: An SGO evidence-based review. 2022
Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis. 2021
The roles of pathology in targeted therapy of women with gynecologic cancers. 2017
Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta-analysis. 2016
Maintaining sexual health throughout gynecologic cancer survivorship: A comprehensive review and clinical guide. 2015
Treatment of ovarian cancer in the older woman. 2014
Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. 2014
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. 2011
Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document. 2011
The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. 2009
Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. 2008
Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. 2006
General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer. 2003
Splenectomy in recurrent epithelial ovarian cancer. 1999
Hepatic resection for metastatic gynecologic carcinomas. 1997
The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. 1997

VIVO Weill Cornell Medical College

Gynecologic oncology Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)